# Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

> **NCT00825487** · PHASE1 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 50 (actual)

## Conditions studied

- Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies

## Interventions

- **DRUG:** ARQ 621

## Key facts

- **NCT ID:** NCT00825487
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2011-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00825487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00825487, "Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00825487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*